|
Vaccination
| | |
|
Duration of vaccine protection
|
Lifetime
|
Assumption
|
|
Age at Vaccination (years)
|
12
|
Assumption
|
|
Vaccine Coverage
|
100%
|
Assumption
|
|
Efficacy: HPV-16/18 (both vaccines)
|
98.0%
|
[26, 46–50]
|
|
HPV-16/18 AS04-adjuvanted Vaccine
| | |
|
Efficacy: Non-vaccine oncogenic HPV types
| | |
|
CIN1
|
47.7% (95% CI: 28.9%, 61.9%)
|
[51]
|
|
CIN2+
|
68.4% (95% CI: 45.7%, 82.4%)
|
[25]
|
|
HPV-6/11/16/18 vaccine Efficacy: Non-vaccine oncogenic HPV types
| |
[27]
|
|
CIN1
|
23.4% (95% CI: 7.8%, 36.4%)
| |
|
CIN2+
|
32.5% (95% CI: 6.0%, 51.9%)
| |
|
HPV-6/11/16/18 Vaccine Efficacy: HPV 6/11
|
98.0%
|
[50]
|
|
Screening
| | |
|
Screening Coverage
| |
[52]
|
|
Age Range
|
18 to 69 years
| |
|
Regular (once/ 3 years)
|
70%
| |
|
Irregular (ages 25, 40, 50)
|
18%
| |
|
Never
|
12%
| |
|
CIN1 detected (sensitivity)
|
42%
|
[44, 52, 53]
|
|
CIN2/3 detected (sensitivity)
|
55%
|
[44, 52, 53]
|
|
% Positive pap Smear
|
5%
|
[44, 52, 53]
|
|
Cost (2006 CAD)
| | |
|
HPV-16/18 AS04-adjuvanted vaccine Cost (per dose)
|
$110.97
|
Assumption
|
|
HPV-6/11/16/18 vaccine Cost (per dose)
|
$110.97
|
Assumption
|
|
Genital Warts treatment (per episode)
|
$207.00
|
[44]
|
|
Cytology Test
|
$57.00
|
[30, 33, 54]
|
|
Colposcopy and biopsy
|
$150.00
|
[30, 33, 54]
|
|
CIN1 treatment and follow-up*
|
$843.00
|
[30, 33, 54]
|
|
CIN2/3 treatment and follow-up*
|
$1 414.00
|
[30, 33, 54]
|
|
Cervical cancer stage 1
|
$11 915.00
|
[30, 33, 54]
|
|
Cervical cancer stage 2
|
$18 851.00
|
[30, 33, 54]
|
|
Cervical cancer stage 3
|
$18 851.00
|
[30, 33, 54]
|
|
Cervical cancer stage 4
|
$25 759.00
|
[30, 33, 54]
|
|
Utility
| | |
|
No HPV, HPV Infection
|
1, 1
| |
|
CIN1 detected
|
0.987
|
[55–58]
|
|
CIN2/3 detected
|
0.991
|
[55–58]
|
|
Cancer treated
|
0.727
|
[55–58]
|
|
Cancer cured
|
0.938
|
[55–58]
|
|
Genital Warts
|
0.980†
|
[59]
|
